List of Invega Hafyera drug patents

Invega Hafyera is owned by Janssen Pharms.

Invega Hafyera contains Paliperidone Palmitate.

Invega Hafyera has a total of 3 drug patents out of which 0 drug patents have expired.

Invega Hafyera was authorised for market use on 18 May, 2015.

Invega Hafyera is available in suspension, extended release;intramuscular dosage forms.

Invega Hafyera can be used as reinitiation of schizophrenia treatment wherein more than 6 months 3 weeks but less than 8 months have elapsed since the last dose, reinitiation of schizophrenia treatment following a missed dose more than 9 months ago; reinitiation of schizophrenia treatment following a missed dose 4-9 months ago, treatment of schizophrenia by administering a dose up to two weeks before or three weeks after the scheduled six-month dose.

The generics of Invega Hafyera are possible to be released after 07 May, 2041.

INVEGA HAFYERA's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10143693 JANSSEN PHARMS Dosing regimen for missed doses for long-acting injectable paliperidone esters
Apr, 2036

(13 years from now)

US11324751 JANSSEN PHARMS Dosing regimens associated with extended release paliperidone injectable formulations
May, 2041

(18 years from now)

US11304951 JANSSEN PHARMS Dosing regimens associated with extended release paliperidone injectable formulations
May, 2041

(18 years from now)

Exclusivity Exclusivity Expiration
New Strength (NS) Aug 30, 2024

Drugs and Companies using PALIPERIDONE PALMITATE ingredient

Market Authorisation Date: 18 May, 2015

Treatment: Reinitiation of schizophrenia treatment following a missed dose more than 9 months ago; Reinitiation of schizophrenia treatment following a missed dose 4-9 months ago; Treatment of schizophrenia by administering a dose up to two weeks before or three weeks after the scheduled six-month dose; Reinitiation of schizophrenia treatment wherein more than 6 months 3 weeks but less than 8 months have elapsed since the last dose

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

How can I launch a generic of INVEGA HAFYERA before it's patent expiration?
More Information on Dosage

INVEGA HAFYERA family patents

4

United States

3

Japan

3

Australia

2

Morocco

2

Canada

2

European Union

1

Portugal

1

Moldova, Republic of

1

Spain

1

Brazil

1

Croatia

1

New Zealand

1

Taiwan, Province of China

1

Korea, Republic of

1

Hong Kong

1

EA

1

Lithuania

1

Hungary

1

Slovenia

1

Ukraine

1

Poland

1

RS

1

Denmark

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic